BURLINGTON, ON, October 30 /CNW/ - The Jenex Corporation (TSX
VENTURE:JEN)(FWB:JNX)(at Yahoo Finance, use (JEN.V)) announced its company
information will be available via S&P's Market Access Program, disseminated to
users of S&P's Advisor Insight, an Internet-based research engine used by more
than 100,000 investment advisors. The information includes all pertinent
financial information. It will also be available via S&P's Stock Guide
database, distributed to virtually all major quote vendors. A full description
will be published in the Daily News section of Standard Corporation Records, a
securities manual for secondary trading in approximately 38 states under Blue
Jenex President Michael Jenkins commented: "We are immensely pleased we
will be featured in S&P's various publications. This is one of our planned
steps to widely publicize Jenex's expansion."
About Jenex: Jenex has a clinically proven non-invasive Medical Device
that is approved for the Prevention of cold sore outbreaks. The
interceptCS(TM) Cold Sore Prevention System is approved in Canada and has
received CE mark approval for European Union countries. interceptCS(TM) is a
new entry into the cold sore treatment market place which currently is being
offered topicals and prescription drugs from companies such as but not limited
to Glaxosmithkline (NYSE: GSK), Novartis (NYSE: NVS), and Zila Inc
(NASDAQ: ZILA). interceptCS(TM) has a superior claim to all other cold sore
products that claim to speed relief after eruption. Jenex, on the other hand
claims "Cold Sore Prevention."
Also, Jenex markets Therapik(R), a device that immediately relieves the
pain & itch caused by the stings & bites of over 20,000 different species of
insects. Therapik(R) is approved in Canada, Australia, and the United States,
as well as having CE Mark approval in the European Union countries. Jenex's
Thermal Therapy technology is patented in the U.S., Canada, Australia, &
Europe. Jenex has the potential to dominate two huge underdeveloped markets.
See www.interceptCS.com and www.JenexCorp.com.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release. Certain
information included in this press release is forward-looking and is subject
to important risks and uncertainties. The results or events predicted in these
statements may differ materially from actual results or events.
For further information:
For further information: The Jenex Corporation Michael Jenkins,
905-632-3830, email@example.com or For S&P Media Relations: Michael